Page 19 - Linical Evolution News Today

Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.

According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.

Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.

The pharma firm has gifted $1m USD to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.

A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.

The US Department of Justice has charged a former CFO and a former head of corporate communications for allegedly conducting an insider trading scheme.

Sited in Pennsylvania, the excipients specialist’s new facility reportedly will work toward advancing drug delivery research and boosting speed to market.

According to a leader from the virtual engagement solutions company, gaps in trial communications can be improved with the intelligent use of technology.

A survey on perceptions toward the decentralized clinical trial format, conducted by Climedo, shows the industry is aware of the benefits but faces barriers

According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.